[Use of semax at a follow-up of patients with posthypoxic encephalopathy].
Alekseeva. G V GV; Bottaev. N A NA; Goroshkova. V V VV
Key Findings
- Semax improved memory‑related symptoms in post‑hypoxic encephalopathy patients.
- The effect was stronger when paired with oxiterm (an adaptogen) and supraorbital electrophoresis.
- EEG monitoring revealed occasional paroxysmal activity after the first semax injection.
Practical Outcomes
- For biohackers, semax might offer modest cognitive benefits in people with brain injury, but its relevance to healthy users is unclear. If experimenting, start with a low dose under EEG or other brain‑activity monitoring, and consider combining it with adaptogens only after safety is confirmed.
Summary
A study gave the brain‑active peptide semax to 73 people who had suffered oxygen‑deprivation injuries. It helped those with memory problems, especially when combined with an adaptogen called oxiterm and a technique called supraorbital electrophoresis. However, some patients showed abnormal brain waves after the first dose, so careful monitoring is advised.
Abstract
Effect of a neuropeptide semax is studied in 73 patients with various symptoms of posthypoxic encephalopathy in remote period. Fourteen of these patients developed a persistent vegetative state. The therapy was effective in patients with mnestic disorders; the drug effect was potentiated by an adaptogen oxiterm and by supraorbital electrophoresis. In some cases EEG showed episodes of paroxysmal activity after semax injection, and therefore, the first injection should be carried out with monitoring bioelectric activity of the brain.
Study Information
pubmed
1999